Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Zhongguo Fei Ai Za Zhi
2013 Dec 01;1612:671-5. doi: 10.3779/j.issn.1009-3419.2013.12.10.
Show Gene links
Show Anatomy links
[Advances of molecular targeted therapy in squamous cell lung cancer].
Ma L
,
Zhang S
.
Abstract
Squamous cell lung cancer (SQCLC) is one of the most prevalent subtypes of lung cancer worldwide, about 400,000 persons die from squamous-cell lung cancer around the world, and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lung adenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, the discoidin domain receptor 2 (DDR2) gene mutation as potential novel targets for the treatment of SQCLCs. Researchers find that there are many specific molecular targeted genes in the genome of squamous-cell lung cancer patients. These changes play a vital role in cell cycle regulation, oxidative stress, cell apoptosis, squamous epithelium differentiation, may be the candidate targeted moleculars in SQCLCs. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lung cancer assessing the value of novel therapeutics addressing these targets.
Bass,
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
2009, Pubmed
Bass,
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.
2009,
Pubmed
Chen,
The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.
2011,
Pubmed
Do,
Rarity of AKT1 and AKT3 E17K mutations in squamous cell carcinoma of lung.
2010,
Pubmed
Drilon,
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.
2012,
Pubmed
Ford,
Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma.
2007,
Pubmed
Forde,
What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
2013,
Pubmed
Hammerman,
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
2011,
Pubmed
Hussenet,
SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis.
2010,
Pubmed
Ji,
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC).
2011,
Pubmed
Ji,
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
2006,
Pubmed
Jin,
PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
2010,
Pubmed
Kawano,
PIK3CA mutation status in Japanese lung cancer patients.
2006,
Pubmed
Kim,
Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.
2010,
Pubmed
Lu,
Evidence that SOX2 overexpression is oncogenic in the lung.
2010,
Pubmed
Massion,
Significance of p63 amplification and overexpression in lung cancer development and prognosis.
2003,
Pubmed
Oh,
Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.
2012,
Pubmed
Ohtsuka,
Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
2007,
Pubmed
Okudela,
PIK3CA mutation and amplification in human lung cancer.
2007,
Pubmed
Pallier,
DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma.
2012,
Pubmed
Rekhtman,
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.
2011,
Pubmed
Rekhtman,
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
2012,
Pubmed
Sarkaria,
Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas.
2006,
Pubmed
Sasaki,
EGFRvIII mutation in lung cancer correlates with increased EGFR copy number.
2007,
Pubmed
Shibata,
Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy.
2008,
Pubmed
Shibata,
Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
2010,
Pubmed
Singh,
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
2006,
Pubmed
Solis,
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
2010,
Pubmed
Song,
Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro.
2013,
Pubmed
Sun,
A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer.
2013,
Pubmed
Tran,
Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer.
2013,
Pubmed
Travis,
Pathology of lung cancer.
2011,
Pubmed
Weiss,
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.
2010,
Pubmed
Wilbertz,
SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.
2011,
Pubmed
Wistuba,
High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints.
2000,
Pubmed
Xu,
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
2012,
Pubmed
